Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy

Meya, David; Rajasingham, Radha; Nalintya, Elizabeth; Tenforde, Mark; Jarvis, Joseph N

doi:10.1007/s40475-015-0045-z

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy

Published Date:

2015

Publisher's site:

http://dx.doi.org/10.1007/s40475-015-0045-z New Site Icon

Source:

Curr Trop Med Rep. 2(2):81-89.

[PDF - 261.55 KB]

Details:

Personal Authors:

Meya, David ; Rajasingham, Radha ; Nalintya, Elizabeth ; Tenforde, Mark ; Jarvis, Joseph N ;

Keywords:

[+]

Pubmed ID:

25960942

Pubmed Central ID:

PMC4412515

Description:

Cryptococcosis remains a significant cause of morbidity and mortality among HIV-infected patients, especially in sub-Saharan Africa where it causes up to 20 % of AIDS-related deaths in HIV programs. A new, highly sensitive, and affordable point of care diagnostic test for cryptococcal infection, the lateral flow assay, can detect early sub-clinical cryptococcosis especially in areas with limited laboratory infrastructure. With a prevalence of detectable sub-clinical cryptococcal infection averaging 7.2 % (95 % CI 6.8-7.6 %) among 36 cohorts with CD4 <100 cells/μL in Africa, together with data showing that preemptive fluconazole prevents overt cryptococcal disease in this population, implementing a screen and treat strategy as part of HIV care practice among patients with CD4 <100 cells/μL could prevent the incidence of often fatal cryptococcal meningitis in the setting of the HIV pandemic.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

U01 AI089244/AI/NIAID NIH HHS/United States
U01 GH000517/GH/CGH CDC HHS/United States
P30 AI045008/AI/NIAID NIH HHS/United States
R01 AI078934/AI/NIAID NIH HHS/United States
R01 AI108479/AI/NIAID NIH HHS/United States
087540/Wellcome Trust/United Kingdom

Supporting Files:

40475_2015_Article_45.nxml

application/octet-stream

No Related Documents.

You May Also Like:

Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era

Personal Author:

Morton, Lindsay M.; Kim, Clara J.; Weiss, Lawrence M.; Bhatia, Kishor; Cockburn, Myles; Hawes, Debra; Wang, Sophia S.; Chang, Cindy; Altekruse, Sean F.; Engels, Eric A.; Cozen, Wendy;

Published:

Jul 29 2013

Source:

Leuk Lymphoma. 55(3):551-557.

Description:

Human immunodeficiency virus (HIV) infection substantially elevates diffuse large B-cell lymphoma (DLBCL) risk, but its impact on the distinct DLBCL subtypes defined by cell of origin is unclear. We compared DLBCL molecular characteristics and progno...

File Type:

[PDF - 309.58 KB]
HIV-associated mortality in the era of antiretroviral therapy scale-up – Nairobi, Kenya, 2015

Personal Author:

Young, Peter W.; Kim, Andrea A.; Wamicwe, Joyce; Nyagah, Lilly; Kiama, Catherine; Stover, John; Oduor, Johansen; Rogena, Emily A.; Walong, Edwin; Zielinski-Gutierrez, Emily; Imbwaga, Andrew; Sirengo, Martin; Kellogg, Timothy A.; De Cock, Kevin M.;

Published:

Aug 02 2017

Source:

PLoS One. 12(8).

Description:

Background : Declines in HIV prevalence and increases in antiretroviral treatment coverage have been documented in Kenya, but population-level mortality associated with HIV has not been directly measured. In urban areas where a majority of deaths pas...

File Type:

[PDF - 533.28 KB]
The Effect of Highly Active Antiretroviral Therapy on the Survival of HIV-Infected Children in a Resource-Deprived Setting: A Cohort Study

Personal Author:

Edmonds, Andrew; Yotebieng, Marcel; Lusiama, Jean; Matumona, Yori; Kitetele, Faustin; Napravnik, Sonia; Cole, Stephen R.; Van Rie, Annelies; Behets, Frieda;

Published:

Jun 14 2011

Source:

PLoS Med. 2011; 8(6).

Description:

Background : The effect of highly active antiretroviral therapy (HAART) on the survival of HIV-infected children has not been well quantified. Because most pediatric HIV occurs in low- and middle-income countries, our objective was to provide a first...

File Type:

[PDF - 269.47 KB]
Survival in XDR TB: Shifting the Curve and Shifting the Paradigm

Personal Author:

Martinson, Neil A.; Chaisson, Richard E.;

Published:

Jun 1 2011

Source:

J Acquir Immune Defic Syndr. 57(2):89-91.

File Type:

[PDF - 30.84 KB]
Maternal Highly Active Antiretroviral Therapy and Child HIV-free Survival in Malawi, 2004-2009

Personal Author:

Schwartz, Sheree R.; Kumwenda, Newton; Kumwenda, Johnstone; Chen, Shu; Mofenson, Lynne M.; Taylor, Allan W.; Fowler, Mary Glenn; Taha, Taha E.;

Published:

Mar 2016

Source:

Matern Child Health J. 20(3):542-549.

Description:

Objectives : Highly active antiretroviral therapy (HAART) provision to eligible HIV-infected pregnant and post-partum women is critical for optimizing maternal health. We assessed the impact of maternal HAART on HIV-free survival of breastfed infants...

File Type:

[PDF - 495.06 KB]